Evidence map›Paper›PMID 32929719›Full record

ArticleBritish journal of pharmacology2020

Preclinical studies investigating the neural mechanisms involved in the co-morbidity of migraine and temporomandibular disorders: the role of CGRP.

Simon Akerman, Marcela Romero-Reyes

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05142228 phase2terminatednot on this mapstarted 2022, after this paper: background citation

Erenumab as a Therapeutic Approach for the Management of Trigeminal Neuropathic Pain (TNP)

TypeinterventionalSponsorUniversity of Maryland, BaltimoreRan2022 to 2022Enrolled5ConditionsTrigeminal NeuropathyArmsErenumab-Aooe, Placebo
NCT05162027 phase2terminatednot on this mapstarted 2022, after this paper: background citation

Erenumab as a Therapeutic Approach for the Management of Painful Chronic Temporomandibular Disorders (TMD)

TypeinterventionalSponsorUniversity of Maryland, BaltimoreRan2022 to 2023Enrolled5ConditionsTemporomandibular DisordersArmsErenumab-Aooe 70 MG in 1 mL Prefilled Syringe, Placebo
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Simon AkermanDepartment of Neural and Pain Sciences, University of Maryland Baltimore, Baltimore, MD, 21201, USA.ORCID 0000-0002-6577-6825
Marcela Romero-ReyesDepartment of Neural and Pain Sciences, University of Maryland Baltimore, Baltimore, MD, 21201, USA.ORCID 0000-0003-0503-0527
University of Maryland, Baltimore · US

Funding

NYUUniversity of Maryland Baltimore
6 · The paper itself

Abstract

background and purposeTemporomandibular disorders (TMD) and migraine can be co-morbid. This can be a significant factor in exacerbating and increasing the prevalence of migraine-like symptoms. However, the underlying mechanisms involved are unknown. Our objective was to investigate these neural mechanisms and the role of CGRP as a key modulator in this co-morbidity. EXPERIMENTAL APPROACH: We combined experimental approaches using CGRP, which triggers a migraine-like response in patients, with that of masseteric muscle injection of complete Freund's adjuvant (CFA), to model myofascial TMD-like inflammation. Using validated electrophysiological methods to assess each of the above approaches independently or in combination, we examined their effects on the response properties of migraine-like dural-trigeminocervical neurons. KEY

resultsIndependently, in ~2/3 of animals (rats) each approach caused delayed migraine-like activation and sensitisation of dural-trigeminocervical neurons. The response to masseteric-CFA was attenuated by a selective CGRP receptor antagonist. The combination approach caused a migraine-like neuronal response in all animals tested, with somatosensory-evoked cranial hypersensitivity significantly exacerbated. CONCLUSION AND IMPLICATIONS: The data demonstrate a neuronal phenotype that translates to the exacerbated clinical co-morbid phenotype, supporting this combination approach as a relevant model to study the mechanisms involved. It provides a pathophysiological rationale for this exacerbated phenotype, strongly implicating the involvement of CGRP. The results provide support for targeting the CGRP pathway as a novel monotherapy approach for treating this co-morbid condition. This has key implications into our understanding of this co-morbid condition, as well as potentially addressing the major unmet need for novel and effective therapeutic approaches.

Indexed as

Migraine DisordersTemporomandibular Joint DisordersAnimalsCalcitonin Gene-Related PeptideFreund's AdjuvantHumansMorbidityRatsCalcitonin Gene-Related PeptideFreund's Adjuvantcentral sensitisationCGRPco-morbidityhypersensitivitymigrainetemporomandibular disorderstrigeminovascular

Identifiers

PMID32929719
PMCPMC7707098
OpenAlexW3086259149

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.